Floatz logo

LETAPLIMAB

Osteosarcoma

Innovent Biologics (Suzhou) Co. Ltd.monoclonal_antibodyPhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
81/ 100

Competitive context

59 Active assets in the Osteosarcoma cohort.

Asset / SponsorPhaseRating
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
(+)-VINCRISTINE
Milton S. Hershey Medical Center
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB

View all 50 →

Same molecule, other indications

LETAPLIMAB is also rated in:

cancerDormant
C
Indicative ·
39 / 100
View asset →
lung adenocarcinomaDormant
C
Indicative ·
37 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →